AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18049294 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 10 mg twice daily
Number of subjects: 16
Study 18049294 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 15 mg twice daily
Number of subjects: 16
Study 18049294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 16087278 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger roofers
Number of subjects: 37
Study 16087278 — intervention group
Group type: EXPERIMENTAL
Intervention: Older roofers
Number of subjects: 37
Study 16087278 — intervention group
Group type: COMPARATOR
Intervention: Older controls
Number of subjects: 37
Study 16087278 — intervention group
Group type: EXPERIMENTAL
Intervention: Work experience
Number of subjects: 37
Study 12407488 — intervention group
Group type: EXPERIMENTAL
Intervention: OBT + T-20
Number of subjects: 547
Study 12407488 — intervention group
Group type: COMPARATOR
Intervention: OBT
Number of subjects: 547
Study 10519608 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group)
Number of subjects: 63
Study 10519608 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group)
Number of subjects: 63
Study 10519608 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRH-a) discontinued before administration of gonadotropins (study group) in patients with non-persistently high basal FSH
Number of subjects: 63
Study 10519608 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (GnRH-a) continued throughout the follicular phase (control group) in patients with non-persistently high basal FSH
Number of subjects: 63
Study 7702030 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E supplementation (900 mg/d for 4 mo)
Number of subjects: 30
Study 1105627 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (10 or 20 mg)
Number of subjects: 10
Study 1105627 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.1 or 0.2 mg)
Number of subjects: 10
Study 1105627 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31234376 — intervention group
Group type: EXPERIMENTAL
Intervention: Gnetin-C
Number of subjects: 12
Study 31234376 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27096396 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational enhancement treatment
Number of subjects: 0
Study 27096396 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management treatment
Number of subjects: 0
Study 27096396 — intervention group
Group type: COMPARATOR
Intervention: Brief educational intervention
Number of subjects: 0
Study 25105516 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620 (0.3, 1, 2 and 4 mg)
Number of subjects: 51
Study 25105516 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620 (1, 2 and 4 mg)
Number of subjects: 51
Study 25105516 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-9620
Number of subjects: 51
Study 25105516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 23727829 — intervention group
Group type: EXPERIMENTAL
Intervention: Identical group
Number of subjects: 0
Study 23727829 — intervention group
Group type: COMPARATOR
Intervention: Random group
Number of subjects: 0
Study 21428241 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg (test formulation)
Number of subjects: 12
Study 21428241 — intervention group
Group type: COMPARATOR
Intervention: Rimonabant 20 mg (reference formulation)
Number of subjects: 12
Study 19231325 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (either percutaneous coronary intervention or coronary artery bypass graft surgery)
Number of subjects: 1773
Study 19231325 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 1773
Study 19231325 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous coronary intervention
Number of subjects: 1773
Study 19231325 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (medical treatment)
Number of subjects: 1773
Study 16987370 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (0.5 microg/kg followed by 0.05 microg/kg/min)
Number of subjects: 100
Study 16987370 — intervention group
Group type: COMPARATOR
Intervention: Propofol (0.5 mg/kg followed by 50 microg/kg/min)
Number of subjects: 100
Study 16987370 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 100
Study 16987370 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 100
Study 14692166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night in addition to a commercially available dentifrice.
Number of subjects: 75
Study 14692166 — intervention group
Group type: COMPARATOR
Intervention: Commercially available dentifrice only.
Number of subjects: 75
Study 14692166 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-whitening gel (Colgate Simply White Night Clear Whitening Gel) used once daily at night.
Number of subjects: 75
Study 10685491 — intervention group
Group type: EXPERIMENTAL
Intervention: CORE program (N = 54)
Number of subjects: 110
Study 10685491 — intervention group
Group type: COMPARATOR
Intervention: Usual care (N = 56)
Number of subjects: 110
Study 9101391 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic men
Number of subjects: 236
Study 9101391 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic women
Number of subjects: 236
Study 9101391 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic men
Number of subjects: 236
Study 9101391 — intervention group
Group type: COMPARATOR
Intervention: Non-diabetic women
Number of subjects: 236
Study 8113493 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent training therapy
Number of subjects: 68
Study 8113493 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretherapy maternal characteristics of inept discipline and antisocial behavior
Number of subjects: 68
Study 8113493 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal depressed mood
Number of subjects: 68
Study 8113493 — intervention group
Group type: EXPERIMENTAL
Intervention: Lack of negative curvature of the resistance growth curves
Number of subjects: 68
Study 3088634 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 3088634 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 0
Study 3088634 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 0
Study 3088634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30859218 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 0
Study 30169192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 3 μg/kg
Number of subjects: 379
Study 30169192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline)
Number of subjects: 379
Study 30169192 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous clonidine 3 μg/kg (in boys)
Number of subjects: 379
Study 30169192 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in boys)
Number of subjects: 379
Study 27439472 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm of the FRAGMATIC trial
Number of subjects: 10
Study 27439472 — intervention group
Group type: COMPARATOR
Intervention: Control arm of the FRAGMATIC trial
Number of subjects: 10
Study 25506618 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor therapy focusing on the nonparetic side along with the conventional program
Number of subjects: 39
Study 25506618 — intervention group
Group type: COMPARATOR
Intervention: Conventional program alone
Number of subjects: 39
Study 21853269 — intervention group
Group type: EXPERIMENTAL
Intervention: L4-5 interspinous space measurements
Number of subjects: 100
Study 21853269 — intervention group
Group type: EXPERIMENTAL
Intervention: L5-S1 interspinous space measurements
Number of subjects: 100
Study 21853269 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of disc height and angle with interspinous height
Number of subjects: 100
Study 21853269 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of measurements with age
Number of subjects: 100
Study 20392347 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (RMP) for 4 months (n = 420)
Number of subjects: 847
Study 20392347 — intervention group
Group type: COMPARATOR
Intervention: Isoniazid for 9 months (n = 427)
Number of subjects: 847
Study 20392347 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP
Number of subjects: 847
Study 20392347 — intervention group
Group type: EXPERIMENTAL
Intervention: RMP and Isoniazid
Number of subjects: 847
Study 18514910 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 sessions of verum acupuncture
Number of subjects: 19
Study 18514910 — intervention group
Group type: COMPARATOR
Intervention: 12 sessions of sham acupuncture (control)
Number of subjects: 19
Study 15881858 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghee diet (10% of energy intake) for 8 weeks
Number of subjects: 63
Study 15881858 — intervention group
Group type: COMPARATOR
Intervention: Mustard oil diet (control) for 8 weeks
Number of subjects: 63
Study 12778975 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion condition (children exploring the maze by walking)
Number of subjects: 144
Study 12778975 — intervention group
Group type: COMPARATOR
Intervention: Non-locomotion condition (children surveying the maze)
Number of subjects: 144
Study 12778975 — intervention group
Group type: EXPERIMENTAL
Intervention: Locomotion condition (children exploring the maze)
Number of subjects: 144
Study 10223020 — intervention group
Group type: EXPERIMENTAL
Intervention: Expert oriented (EXP) bulletin
Number of subjects: 0
Study 10223020 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual and pastor-oriented (SPIR) bulletin
Number of subjects: 0
Study 10223020 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 8709183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and IVGG 400 mg/kg/day for 5 consecutive days
Number of subjects: 293
Study 8709183 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and single high dose IVGG (2 gm/kg) for 10-12 hours
Number of subjects: 293
Study 8709183 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 293
Study 1882923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobunolol
Number of subjects: 80
Study 1882923 — intervention group
Group type: COMPARATOR
Intervention: 0.25% timolol
Number of subjects: 80
Study 7090992 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial stimulation
Number of subjects: 10
Study 7090992 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular stimulation
Number of subjects: 10
Study 31014147 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine treatment group (n=25)
Number of subjects: 49
Study 31014147 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline, n=24)
Number of subjects: 49
Study 31014147 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 29785101 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium 18 µg once-daily maintenance therapy
Number of subjects: 140
Study 29785101 — intervention group
Group type: COMPARATOR
Intervention: Standard care for AECOPD and RTI
Number of subjects: 140
Study 27821982 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone with Vaginal Misoprostol (Group-A)
Number of subjects: 280
Study 27821982 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group-B)
Number of subjects: 280
Study 24700398 — intervention group
Group type: EXPERIMENTAL
Intervention: CC/Gn/GnRH‐ant 'mild' protocol
Number of subjects: 695
Study 24700398 — intervention group
Group type: COMPARATOR
Intervention: GnRH‐agonist and high‐dose Gn 'long' protocol
Number of subjects: 695
Study 24700398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 695
Study 23081661 — intervention group
Group type: EXPERIMENTAL
Intervention: Image-guided surgery
Number of subjects: 20
Study 23081661 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 20
Study 19399499 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile bearing type
Number of subjects: 68
Study 19399499 — intervention group
Group type: COMPARATOR
Intervention: Fixed bearing type
Number of subjects: 68
Study 17459013 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported willingness-to-pay (WTP) for a theoretical treatment with a cure rate of 85%
Number of subjects: 46
Study 17459013 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported annual income
Number of subjects: 46
Study 15226331 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan (1.5 mg/m² on days 1 through 5, four cycles, every 3 weeks)
Number of subjects: 273
Study 15226331 — intervention group
Group type: COMPARATOR
Intervention: Observation (control group)
Number of subjects: 273
Study 15226331 — intervention group
Group type: EXPERIMENTAL
Intervention: Topotecan
Number of subjects: 273
Study 11343045 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg added to budesonide 200 microg twice daily
Number of subjects: 279
Study 11343045 — intervention group
Group type: COMPARATOR
Intervention: Placebo added to budesonide 200 microg twice daily
Number of subjects: 279
Study 9633737 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone 10 mg every 12 hours, increased weekly up to a maximum of 30 mg every 12 hours
Number of subjects: 50
Study 9633737 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release oxycodone
Number of subjects: 50
Study 7869315 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 24
Study 7869315 — intervention group
Group type: EXPERIMENTAL
Intervention: SPECT
Number of subjects: 24
Study 7869315 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI and SPECT combined
Number of subjects: 24
Study 3348138 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate 10 mg
Number of subjects: 50
Study 3348138 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate 20 mg
Number of subjects: 50
Study 3348138 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide‐5‐mononitrate 50 mg
Number of subjects: 50
Study 3348138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 31651661 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-effects ordinary least squares (OLS)
Number of subjects: 0
Study 31651661 — intervention group
Group type: EXPERIMENTAL
Intervention: Conditional logistic regression
Number of subjects: 0
Study 31651661 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratified Cox regression
Number of subjects: 0
Study 30269642 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 300 mg
Number of subjects: 43
Study 30269642 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 600 mg
Number of subjects: 43
Study 30269642 — intervention group
Group type: EXPERIMENTAL
Intervention: Solriamfetol 1200 mg
Number of subjects: 43
Study 30269642 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 45 mg
Number of subjects: 43
Study 30269642 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentermine 90 mg
Number of subjects: 43
Study 30269642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 27599874 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced performance feedback
Number of subjects: 67
Study 27599874 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced performance feedback plus patient participation
Number of subjects: 67
Study 27599874 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 67
Study 24743717 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine 10 mg/d
Number of subjects: 49
Study 24743717 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular haloperidol 7.5 mg/d
Number of subjects: 49
Study 24743717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 22549239 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprocare®XR 1000 mg ciprofloxacin (test formulation)
Number of subjects: 24
Study 22549239 — intervention group
Group type: COMPARATOR
Intervention: Cipro®XR sustained release tablet (reference formulation)
Number of subjects: 24
Study 20927040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration rates over 13 ml/h/kg
Number of subjects: 1846
Study 20927040 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrafiltration rates between 10-13 ml/h/kg
Number of subjects: 1846
Study 20927040 — intervention group
Group type: COMPARATOR
Intervention: Ultrafiltration rates up to 10 ml/h/kg
Number of subjects: 1846
Study 18218556 — intervention group
Group type: COMPARATOR
Intervention: No activation
Number of subjects: 250
Study 18218556 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular activation
Number of subjects: 250
Study 18218556 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation on an as-needed basis
Number of subjects: 250
Study 17081405 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (no parental history of hypertension)
Number of subjects: 15131
Study 17081405 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (one parent history of hypertension)
Number of subjects: 15131
Study 17081405 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (both parents history of hypertension)
Number of subjects: 15131
Study 17081405 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2 (one parent history of hypertension) after adjusting for serum total cholesterol, HDL-C, fasting glucose, BMI, and SBP
Number of subjects: 15131
Study 17081405 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (both parents history of hypertension) after adjusting for serum total cholesterol, HDL-C, fasting glucose, BMI, and SBP
Number of subjects: 15131
Study 12824787 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 479
Study 10825337 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 0.15 mg oral dose 90 min before surgery
Number of subjects: 20
Study 10825337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no premedication)
Number of subjects: 20
Study 8677193 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarction
Number of subjects: 0
Study 8677193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 1725027 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg of ramipril
Number of subjects: 0
Study 1725027 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of ramipril
Number of subjects: 0
Study 1725027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6440793 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 15-1788 30 mg (2 tablets)
Number of subjects: 6
Study 31027098 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with methylene blue (MB) at 0.005% concentration and low intensity laser irradiation (λ = 660 nm, 9J per point, radiant exposure of 318 J/cm)
Number of subjects: 64
Study 31027098 — intervention group
Group type: COMPARATOR
Intervention: Irrigation with sterile saline and PDT (conventional MB at 0.005% concentration and irradiation with low intensity laser λ = 660 nm, 9J per point and radiant exposure of 318 J/cm)
Number of subjects: 64
Study 29750547 — intervention group
Group type: EXPERIMENTAL
Intervention: Definitely called during the night
Number of subjects: 0
Study 29750547 — intervention group
Group type: EXPERIMENTAL
Intervention: Maybe called during the night
Number of subjects: 0
Study 29750547 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no on-call)
Number of subjects: 0
Study 26864411 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Skill Acquisition Program (ASAP)
Number of subjects: 361
Study 26864411 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-equivalent occupational therapy (DEUCC)
Number of subjects: 361
Study 26864411 — intervention group
Group type: COMPARATOR
Intervention: Monitoring-only occupational therapy (UCC)
Number of subjects: 361
Study 24499460 — intervention group
Group type: EXPERIMENTAL
Intervention: Differentiated resistance training
Number of subjects: 60
Study 24499460 — intervention group
Group type: COMPARATOR
Intervention: Respiratory therapy (Control)
Number of subjects: 60
Study 22869344 — intervention group
Group type: EXPERIMENTAL
Intervention: Older caregivers
Number of subjects: 1219
Study 20658807 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-child cognitive behavioral therapy (CBT)
Number of subjects: 64
Study 20658807 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 64
Study 18025310 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenotonsillectomy
Number of subjects: 300
Study 18025310 — intervention group
Group type: COMPARATOR
Intervention: Watchful waiting
Number of subjects: 300
Study 16110025 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF (docetaxel 75 mg/m2, cisplatin 75 mg/m2 on day 1, and fluorouracil 750 mg/m2/d as continuous infusion on days 1 to 5)
Number of subjects: 158
Study 16110025 — intervention group
Group type: COMPARATOR
Intervention: DC (docetaxel 85 mg/m2 and cisplatin 75 mg/m2 on day 1)
Number of subjects: 158
Study 16110025 — intervention group
Group type: EXPERIMENTAL
Intervention: DCF
Number of subjects: 158
Study 16110025 — intervention group
Group type: COMPARATOR
Intervention: DC
Number of subjects: 158
Study 12126721 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV prophylaxis (group Z)
Number of subjects: 117
Study 12126721 — intervention group
Group type: COMPARATOR
Intervention: Control (group C)
Number of subjects: 117
Study 12126721 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic infants (group Z)
Number of subjects: 117
Study 9649697 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 10 minutes
Number of subjects: 59
Study 9649697 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 20 minutes
Number of subjects: 59
Study 9649697 — intervention group
Group type: EXPERIMENTAL
Intervention: EMLA cream applied for 60 minutes
Number of subjects: 59
Study 8834128 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic home oxygen therapy (mean 16.4 h/day) with standard pharmacological treatment (prednisone 10‐15 mg/day) for 4 years
Number of subjects: 18